ALLOVIR INC (ALVR)
US0198181036 - Common Stock
Taking everything into account, ALVR scores 3 out of 10 in our fundamental rating. ALVR was compared to 565 industry peers in the Biotechnology industry. While ALVR has a great health rating, there are worries on its profitability. ALVR has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year ALVR has reported negative net income.
ALVR had a negative operating cash flow in the past year.
ALVR had negative earnings in each of the past 5 years.
ALVR had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -81.77%, ALVR is doing worse than 70.28% of the companies in the same industry.
Looking at the Return On Equity, with a value of -82.73%, ALVR is in line with its industry, outperforming 51.07% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -81.77% | ||
| ROE | -82.73% | ||
| ROIC | N/A |
ROA(3y)-73.56%
ROA(5y)-51.32%
ROE(3y)-94.03%
ROE(5y)-64.29%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ALVR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ALVR has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ALVR has more shares outstanding
ALVR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
ALVR has an Altman-Z score of 10.92. This indicates that ALVR is financially healthy and has little risk of bankruptcy at the moment.
ALVR's Altman-Z score of 10.92 is amongst the best of the industry. ALVR outperforms 87.37% of its industry peers.
There is no outstanding debt for ALVR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 10.92 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 86.78 indicates that ALVR has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 86.78, ALVR belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
ALVR has a Quick Ratio of 86.78. This indicates that ALVR is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of ALVR (86.78) is better than 100.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 86.78 | ||
| Quick Ratio | 86.78 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 25.78% over the past year.
EPS 1Y (TTM)25.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90.83%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to grow by 20.08% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y69.66%
EPS Next 2Y35.01%
EPS Next 3Y20.08%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ALVR. In the last year negative earnings were reported.
Also next year ALVR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
ALVR's earnings are expected to grow with 20.08% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.01%
EPS Next 3Y20.08%
5. Dividend
5.1 Amount
No dividends for ALVR!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ALLOVIR INC
NASDAQ:ALVR (12/23/2024, 8:00:00 PM)
0.45
+0.05 (+11.39%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners41.77%
Inst Owner Change-4.27%
Ins Owners7.35%
Ins Owner Change-0.37%
Market Cap51.99M
Analysts43.33
Price Target1.53 (240%)
Short Float %3.25%
Short Ratio4.93
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)53.85%
PT rev (3m)53.85%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.43 | ||
| P/tB | 0.43 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.67
EYN/A
EPS(NY)-0.3
Fwd EYN/A
FCF(TTM)-0.82
FCFYN/A
OCF(TTM)-0.82
OCFYN/A
SpS0
BVpS1.05
TBVpS1.05
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -81.77% | ||
| ROE | -82.73% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-73.56%
ROA(5y)-51.32%
ROE(3y)-94.03%
ROE(5y)-64.29%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 86.78 | ||
| Quick Ratio | 86.78 | ||
| Altman-Z | 10.92 |
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90.83%
EPS Next Y69.66%
EPS Next 2Y35.01%
EPS Next 3Y20.08%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y55.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year63.06%
EBIT Next 3Y18.66%
EBIT Next 5YN/A
FCF growth 1Y31.34%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y31.53%
OCF growth 3YN/A
OCF growth 5YN/A